Alliancebernstein L.P. Raises Stock Holdings in Insulet Corporation $PODD

Key Points

• Alliancebernstein L.P. increased its holdings in Insulet Corporation by 4.0%, owning a total of 98,574 shares valued at approximately $25.89 million.
• Several other institutional investors have also boosted their positions in Insulet, with significant increases from Captrust Financial Advisors (24.1%) and Gotham Asset Management (57.2%) during the fourth quarter.
• Insulet's recent quarterly earnings surpassed expectations, reporting an EPS of $1.17, a 32.9% revenue increase from the previous year, and the company has strong analyst ratings with 16 buy ratings and a consensus average target price of $335.12.

Alliancebernstein L.P. raised its stake in Insulet Corporation (NASDAQ:PODD - Free Report) by 4.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 98,574 shares of the medical instruments supplier's stock after buying an additional 3,815 shares during the period. Alliancebernstein L.P. owned about 0.14% of Insulet worth $25,887,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Vanguard Group Inc. grew its position in shares of Insulet by 2.1% in the 1st quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier's stock valued at $2,276,553,000 after buying an additional 178,976 shares during the last quarter. American Century Companies Inc. grew its position in shares of Insulet by 34.8% in the 1st quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier's stock valued at $302,686,000 after buying an additional 297,734 shares during the last quarter. Groupama Asset Managment grew its position in shares of Insulet by 0.4% in the 1st quarter. Groupama Asset Managment now owns 1,053,759 shares of the medical instruments supplier's stock valued at $276,728,000 after buying an additional 3,759 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Insulet by 4.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 674,367 shares of the medical instruments supplier's stock valued at $177,096,000 after buying an additional 27,408 shares during the last quarter. Finally, GAMMA Investing LLC boosted its position in shares of Insulet by 27,298.6% during the 1st quarter. GAMMA Investing LLC now owns 664,141 shares of the medical instruments supplier's stock valued at $1,744,100,000 after purchasing an additional 661,717 shares in the last quarter.

Insulet Stock Up 1.1%

Shares of Insulet stock traded up $3.84 on Friday, hitting $341.78. The company had a trading volume of 472,873 shares, compared to its average volume of 530,837. The stock has a market capitalization of $24.06 billion, a price-to-earnings ratio of 103.88, a P/E/G ratio of 2.81 and a beta of 1.36. Insulet Corporation has a 1 year low of $225.37 and a 1 year high of $353.50. The stock has a 50 day moving average of $311.59 and a 200-day moving average of $291.99. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, topping the consensus estimate of $0.92 by $0.25. The firm had revenue of $649.10 million during the quarter, compared to the consensus estimate of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The company's quarterly revenue was up 32.9% compared to the same quarter last year. During the same period in the prior year, the business posted $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, sell-side analysts forecast that Insulet Corporation will post 3.92 earnings per share for the current year.

Wall Street Analyst Weigh In

PODD has been the topic of several research analyst reports. Morgan Stanley restated an "overweight" rating on shares of Insulet in a research report on Thursday, August 7th. Truist Financial initiated coverage on Insulet in a research report on Monday, June 16th. They set a "buy" rating and a $365.00 target price on the stock. Jefferies Financial Group restated a "buy" rating on shares of Insulet in a research report on Thursday, August 7th. Barclays increased their price target on Insulet from $266.00 to $300.00 and gave the stock an "equal weight" rating in a report on Thursday, August 21st. Finally, Oppenheimer increased their price target on Insulet from $324.00 to $365.00 and gave the stock an "outperform" rating in a report on Monday. Sixteen research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $335.12.

Insider Activity at Insulet

In other news, SVP Laetitia Cousin sold 797 shares of the stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the sale, the senior vice president directly owned 3,890 shares of the company's stock, valued at $1,356,870.90. This represents a 17.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Prem Singh sold 687 shares of the stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the sale, the senior vice president directly owned 3,456 shares of the company's stock, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.39% of the company's stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.